Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Idiopatisk lungefibrose og interstitiel lungesygdom Prospektive udfaldsregister (IPF/ILD-PRO)

9. november 2026 opdateret af: Duke University

Idiopatisk lungefibrose prospektive udfald (IPF-PRO) og kronisk fibroserende interstitiel lungesygdom med progressive fænotype prospektive udfald (IPF-PRO/ILD-PRO) register

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

3000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • Rekruttering
        • University of Alabama - Birmingham
        • Ledende efterforsker:
          • Tejaswini Kulkarni, MD
        • Kontakt:
    • Arizona
      • Tucson, Arizona, Forenede Stater, 85721
        • Rekruttering
        • University of Arizona
        • Ledende efterforsker:
          • Sally A Suliman, MD
        • Kontakt:
    • California
      • Los Angeles, California, Forenede Stater, 90033
        • Rekruttering
        • University of Southern California
        • Kontakt:
        • Ledende efterforsker:
          • Toby Maher, MD
      • Los Angeles, California, Forenede Stater, 90024
        • Rekruttering
        • University of California - Los Angeles
        • Ledende efterforsker:
          • John Belperio, MD
        • Kontakt:
      • Stanford, California, Forenede Stater, 94305
        • Rekruttering
        • Stanford University
        • Ledende efterforsker:
          • Rishi Raj, MD
        • Kontakt:
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • University of Colorado
        • Ledende efterforsker:
          • Joyce Lee, MD
        • Kontakt:
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06520
        • Rekruttering
        • Yale University
        • Ledende efterforsker:
          • Mridu Gulati, MD
        • Kontakt:
    • Florida
      • Gainesville, Florida, Forenede Stater, 32610-3175
      • Tampa, Florida, Forenede Stater, 33606
        • Rekruttering
        • University of South Florida
        • Ledende efterforsker:
          • Jose D Herazo-Maya, MD
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University
        • Kontakt:
        • Ledende efterforsker:
          • Srihari Veeraraghavan, MD
      • Austell, Georgia, Forenede Stater, 30106
        • Rekruttering
        • Piedmont Healthcare
        • Ledende efterforsker:
          • Amy Case, MD
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • University of Chicago
        • Ledende efterforsker:
          • Mary Strek, MD
        • Kontakt:
      • Evanston, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Northwestern University
        • Kontakt:
        • Ledende efterforsker:
          • Bradford Bemiss, MD
      • Maywood, Illinois, Forenede Stater, 60153
        • Rekruttering
        • Loyola University Health System
        • Ledende efterforsker:
          • Daniel Dilling, MD
        • Kontakt:
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Afsluttet
        • University of Kansas
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40536
        • Rekruttering
        • University of Kentucky
        • Ledende efterforsker:
          • Girish Nair, MD
        • Kontakt:
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70112
        • Rekruttering
        • Tulane University
        • Ledende efterforsker:
          • Joe Lasky, MD
        • Kontakt:
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Aktiv, ikke rekrutterende
        • University of Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Rekruttering
        • Henry Ford Health
        • Kontakt:
        • Ledende efterforsker:
          • Asif Abdul Hameed, MD
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • Rekruttering
        • University of Minnesota
        • Kontakt:
        • Ledende efterforsker:
          • Hyum Kim, MD
    • Mississippi
      • Jackson, Mississippi, Forenede Stater, 39216
        • Rekruttering
        • University of Mississippi Medical Center
        • Ledende efterforsker:
          • Kimberly Dobbs, MD
        • Kontakt:
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University
        • Ledende efterforsker:
          • Tonya Russell, MD
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Weill Medical College of Cornell University
        • Ledende efterforsker:
          • Kerri Aronson, MD
        • Kontakt:
      • New York, New York, Forenede Stater, 10016
        • Aktiv, ikke rekrutterende
        • NYU Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27514
      • Durham, North Carolina, Forenede Stater, 27705
        • Rekruttering
        • Duke University
        • Ledende efterforsker:
          • Lake Morrison, MD
        • Kontakt:
      • Greensboro, North Carolina, Forenede Stater, 27403
        • Rekruttering
        • Pulmonix LLC
        • Ledende efterforsker:
          • Murali Ramaswamy, MD
        • Kontakt:
      • Wilmington, North Carolina, Forenede Stater, 28401
        • Afsluttet
        • PMG Research
      • Winston-Salem, North Carolina, Forenede Stater, 27157
        • Rekruttering
        • Wake Forest Baptist Health
        • Kontakt:
        • Ledende efterforsker:
          • Andrew Namen, MD
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45267
        • Aktiv, ikke rekrutterende
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Cleveland Clinic
        • Ledende efterforsker:
          • Brian Southern, MD
        • Kontakt:
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • The Ohio State University
        • Kontakt:
        • Ledende efterforsker:
          • John Odackal
    • Oklahoma
      • Oklahoma City, Oklahoma, Forenede Stater, 73104
        • Rekruttering
        • University of Oklahoma
        • Ledende efterforsker:
          • Jad Kebbe, MD
        • Kontakt:
    • Oregon
      • Portland, Oregon, Forenede Stater, 97220
        • Rekruttering
        • Oregon Clinic
        • Ledende efterforsker:
          • David Hotchkin, MD
        • Kontakt:
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Rekruttering
        • Penn State College of Medicine - Hershey
        • Ledende efterforsker:
          • Rebecca Bascom, MD
        • Kontakt:
      • Philadelphia, Pennsylvania, Forenede Stater, 19140
      • Philadelphia, Pennsylvania, Forenede Stater, 19144
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Rekruttering
        • Medical University of South Carolina
        • Ledende efterforsker:
          • Timothy Whelan, MD
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
        • Rekruttering
        • Vanderbilt University
        • Kontakt:
        • Ledende efterforsker:
          • Justin Hewlett, MD
    • Texas
      • Dallas, Texas, Forenede Stater, 75235
        • Rekruttering
        • University of Texas Southwestern
        • Ledende efterforsker:
          • John Fitzgerald, MD
        • Kontakt:
      • Dallas, Texas, Forenede Stater, 75246
        • Rekruttering
        • Baylor University Medical Center at Dallas
        • Ledende efterforsker:
          • Yolanda Mageto, MD
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Baylor College of Medicine
        • Ledende efterforsker:
          • Ivan Rosas, MD
        • Kontakt:
      • Houston, Texas, Forenede Stater, 77030
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • The University of Texas Health Science Center At Houston
        • Ledende efterforsker:
          • Rodeo Abrencillo, MD
        • Kontakt:
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84108
        • Rekruttering
        • University of Utah
        • Kontakt:
        • Ledende efterforsker:
          • Mary Beth Langer, MD
      • Salt Lake City, Utah, Forenede Stater, 84111
        • Rekruttering
        • Intermountain Health
        • Kontakt:
        • Ledende efterforsker:
          • Erin Blackstock, MD
    • Vermont
      • Colchester, Vermont, Forenede Stater, 05446
        • Aktiv, ikke rekrutterende
        • University of Vermont Lung Center
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22908
        • Aktiv, ikke rekrutterende
        • University from Virginia
      • Falls Church, Virginia, Forenede Stater, 22042-3307
        • Rekruttering
        • Inova Health Care Services
        • Kontakt:
        • Ledende efterforsker:
          • Jared Wilkinson, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Aktiv, ikke rekrutterende
        • The Medical College of Wisconsin

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

Beskrivelse

Inclusion Criteria:

  • Willing and able to provide informed consent

  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.

  • Age 21 years or older, or

  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.

    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion Criteria:

  • Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

Subjects with a non-IPF ILD diagnosis

Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

New Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Tidsramme: End of Study (3 years after last patient will be enrolled)

Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

End of Study (3 years after last patient will be enrolled)
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Tidsramme: End of Study (3 years after last patient will be enrolled)

Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

End of Study (3 years after last patient will be enrolled)
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Tidsramme: End of Study (3 years after last patient will be enrolled)

Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

End of Study (3 years after last patient will be enrolled)
Blood samples for future research.
Tidsramme: End of Study (3 years after last patient will be enrolled)

Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

End of Study (3 years after last patient will be enrolled)
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Tidsramme: End of Study (3 years after last patient will be enrolled)

Collect longitudinal HRCT images for future research

End of Study (3 years after last patient will be enrolled)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Data on management practices compared to existing guidelines.
Tidsramme: End of Study (3 years after last patient will be enrolled)

Compare disease-specific management practices with existing guidelines.

End of Study (3 years after last patient will be enrolled)
Data on center-specific practices on outcomes.
Tidsramme: End of Study (3 years after last patient will be enrolled)

Determine the influence of center-specific practices on patient outcomes.

End of Study (3 years after last patient will be enrolled)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Scott Palmer, MD, Duke Clinical Research Institute, Duke University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juni 2014

Primær færdiggørelse (Anslået)

1. januar 2028

Studieafslutning (Anslået)

1. januar 2031

Datoer for studieregistrering

Først indsendt

31. juli 2013

Først indsendt, der opfyldte QC-kriterier

1. august 2013

Først opslået (Anslået)

5. august 2013

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • Pro00046131
  • 1199.174 (Anden identifikator: DCRI)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .